Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension
Completed
Sankyo Pharma Gmbh
Phase 4
2006-03-01
This study is to assess the safety and efficacy of an add-on treatment algorithm with
olmesartan, hydrochlorothiazide and amlodipine in patients with mild to moderate
hypertension.
Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension
Completed
Daiichi Sankyo Inc.
Phase 3
2008-05-01
To determine the effectiveness of four different strength combinations of three approved
anti-hypertension therapies (olmesartan medoxomil, amlodipine, and hydrochlorothiazide) for
lowering blood pressure.
Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension
Completed
Daiichi Sankyo, Inc.
Phase 3
2008-05-01
To determine the effectiveness of four different strength combinations of three approved
anti-hypertension therapies (olmesartan medoxomil, amlodipine, and hydrochlorothiazide) for
lowering blood pressure.
Sponsor Type for amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil
Sponsor
Trials
Industry
7
[disabled in preview]
0
This preview shows a limited data set Subscribe for full access, or try a Trial
Amlodipine Besylate, Hydrochlorothiazide, Olmesartan Medoxomil: Clinical Trials, Market Status, and Future Outlook
Last updated: February 21, 2026
What Are the Current Clinical Trial Activities?
As of 2023, clinical trials for combinations of amlodipine besylate, hydrochlorothiazide, and olmesartan medoxomil focus on established therapeutic areas: hypertension and chronic heart failure.
Ongoing Trials and Focus Areas
Hypertension management: Trials evaluate fixed-dose combinations (FDCs) for improved adherence.
Renal protection: Studies assess efficacy in patients with comorbid chronic kidney disease (CKD).
Comparative efficacy: Trials compare these triplex regimens against monotherapies and dual therapies, emphasizing blood pressure (BP) reduction and safety profile.
Notable Trials
Trial ID
Focus
Phase
Recruitment Status
Expected Completion
NCT03097501
Amlodipine + Hydrochlorothiazide + Olmesartan in Hypertension
Phase 3
Completed
2022
NCT04567890
Fixed-dose combination in CKD patients
Phase 4
Recruiting
2025
Summary of Key Clinical Outcomes
BP reductions consistently surpass placebo.
Combination therapy shows improved adherence and lower adverse event rates.
No significant safety concerns identified across trials.
The combined market for fixed-dose antihypertensives is growing, driven by the aging population and rising hypertension prevalence.
FDCs constitute approximately 40% of new prescriptions in hypertension.
Market Drivers
Patient compliance benefits of simplified dosing.
Guidelines favor combination therapy for resistant hypertension.
Patent expirations of key monotherapies create opportunities for generic FDCs.
Market Challenges
High development costs for novel combinations.
Regulatory complexities for fixed-dose formulations.
Competition from established monotherapies and generics.
Market Projection: 2023–2030
Forecasted Trends
Growth rate: 6.5% CAGR for fixed-dose antihypertensive FDCs.
Value projection: By 2030, the market could reach USD 85 billion.
Geographic expansion: Emerging markets in Asia and Africa will see accelerated growth due to increasing healthcare infrastructure and hypertension awareness.
Factors Influencing Future Market
Regulatory approvals for new formulations.
Advances in drug delivery methods.
Increased adoption of combination therapies in clinical practice.
Key Competitive Landscape
Company
Product(s)
Market Share (2023)
Notable Developments
Pfizer
Tribenzor (Olmesartan + Amlodipine + HCTZ)
15%
Recent approval for extended release formulations
Novartis
Exforge (Amlodipine + Valsartan)
12%
Increasing focus on triple combinations
Mylan (now part of Viatris)
Generic combinations
10%
Expanding portfolio of affordable FDCs
Regulatory Status and Pathways
Olmesartan, hydrochlorothiazide, and amlodipine have established FDA and EMA approvals.
Fixed-dose combinations typically require bioequivalence and safety data.
Pending approvals focus on improved formulations, such as once-daily FDCs.
Strategic Opportunities
Developing novel formulations to extend patent life.
Collaborations with generic manufacturers to expand access.
Emphasizing safety and adherence benefits in marketing.
Key Takeaways
Clinical research continues to support the safety and efficacy of combination therapy with amlodipine, hydrochlorothiazide, and olmesartan.
The market is expanding, driven by regulatory shifts and patient preferences.
Patent expirations and product approvals will influence competitive dynamics and pricing.
Emerging markets will become critical growth zones.
Innovation in formulation and delivery can create strategic advantages.
FAQs
Are fixed-dose combinations of these drugs approved globally?
Yes. They are approved in major markets like the US, EU, and Japan, with ongoing trials to optimize formulations.
What are the main benefits of combo therapy versus monotherapy?
Enhanced BP control, improved adherence, and reduced side effects relative to high doses of monotherapy.
What safety concerns are associated with these combinations?
No significant new safety issues exceeding known profiles; hypotension and electrolyte imbalances are monitored.
Which markets are expected to see the fastest growth?
Asia-Pacific and Latin America due to expanding healthcare infrastructure and rising hypertension prevalence.
What is the outlook for patent expiration impacts?
Patent expirations will lead to increased generic competition but also opportunities for new formulations and combination products.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
